Impact of the COVID‐19 Pandemic on Parkinson's Disease and Movement Disorders

Yerkes National Primate Research Center, Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA Van Andel Institute, Center for Neurodegenerative Science, Grand Rapids, Michigan, USA Movement Disorders Unit, Department of Neurology, Westmead Hospital and Sydney Medical School, University of Sydney, Sydney, NSW, Australia Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA Department of Medical Sciences, Newcastle University Medical School, Newcastle, United Kingdom Department of Neurology, Santa Maria University Hospital, Terni, Italy Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA Paracelsus-Elena Klinik, Kassel, Department of Neurosurgery, University Medical Center, Goettingen, Goettingen, Germany

[1]  J. Fleming,et al.  Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  Y. Sunden,et al.  Vet Pathol 41:101–107 (2004) The Vagus Nerve is One Route of Transneural Invasion for , 2022 .

[3]  G. Dunn,et al.  Evidence for an enterovirus as the cause of encephalitis lethargica , 2012, BMC Infectious Diseases.

[4]  A. Souza-Machado,et al.  The effect of levodopa on pulmonary function in Parkinson's disease: a systematic review and meta-analysis. , 2012, Clinical therapeutics.

[5]  S. Tisch,et al.  Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  David K Meyerholz,et al.  Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4 , 2015, The Journal of infectious diseases.

[7]  B. Guthrie,et al.  Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database , 2017, BMC Neurology.

[8]  H. Yasunaga,et al.  Influence of Parkinsonism on outcomes of elderly pneumonia patients. , 2018, Parkinsonism & related disorders.

[9]  D. Wesson,et al.  The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases , 2016, Neurobiology of Disease.

[10]  Z. Mari,et al.  The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach , 2018, Current Neurology and Neuroscience Reports.

[11]  L. Brundin,et al.  Can infections trigger alpha-synucleinopathies? , 2019, Progress in molecular biology and translational science.

[12]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[13]  NacotiMirco,et al.  At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation , 2020 .

[14]  Quanyi Wang,et al.  Viral load of SARS-CoV-2 in clinical samples , 2020, The Lancet Infectious Diseases.

[15]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[16]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[17]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[18]  A. Wilder-Smith,et al.  Can we contain the COVID-19 outbreak with the same measures as for SARS? , 2020, The Lancet Infectious Diseases.

[19]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[20]  Tsutomu Hashikawa,et al.  The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients , 2020, Journal of medical virology.

[21]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[22]  T. Hashikawa,et al.  Response to Commentary on: "The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients". , 2020, Journal of medical virology.

[23]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[24]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[25]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[26]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[27]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[28]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[29]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.